DOSING REGIMENS AND METHODS FOR TREATING CANCER
The invention provides methods for treating cancer in a patient comprising administering dosing regimens of (S,S)-(HO)2DEHSPM that unexpectedly reverse or reduce the onset of severe liver toxicity and improve patient safety profiles.
1 . A method for treating cancer in a patient comprising administering to a patient in need thereof, a dosing regimen of (S,S)-(HO)2DEHSPM, wherein the dosing regimen comprises administering (S,S)-(HO)2DEHSPM daily for 5 consecutive days of each treatment cycle for no more than two 4 consecutive treatment cycles wherein each treatment cycle is about 28 days.
2 . The method of claim 1 , wherein the dosing regimen comprises administering (S,S)-(HO)2DEHSPM daily for 5 consecutive days for no more than two consecutive treatment cycles.
3 . The method of claim 1 , wherein the daily free base equivalent dose of (S,S)-(HO)2DEHSPM is selected from about 0.14 mg/kg/day, about 0.27 mg/kg/day, and about 0.41 mg/kg/day.
4 - 7 . (canceled)
8 . The method of claim 1 , further comprising co-administering gemcitabine (GEM) or nab-paclitaxel (NAB) or both GEM and NAB (GEM/NAB) with (S,S)-(HO)2DEHSPM for at least one treatment cycle.
9 . The method of claim 8 , wherein co-administration comprises administering gemcitabine (GEM) or nab-paclitaxel (NAB) or both GEM and NAB (GEM/NAB) on days 1, 8 and 15 of at least one treatment cycle.
10 . (canceled)
11 . The method of claim 10 , further comprising administering (S,S)-(HO)2DEHSPM periodically during a treatment cycle subsequent to treatment cycle 2 wherein periodic administration comprises no more than 14 doses of (S,S)-(HO)2DEHSPM administered on non-consecutive days.
12 - 13 . (canceled)
14 . A method for treating cancer in a patient in need thereof comprising administering to the patient, a dosing regimen of (S,S)-(HO)2DEHSPM wherein the dosing regimen comprises administering (S,S)-(HO)2DEHSPM daily for 5 consecutive days during the first week of each treatment cycle for two consecutive treatment cycles, wherein each treatment cycle is about 28 days, followed by administering (S,S)-(HO)2DEHSPM periodically on days 1, 8 and 15 during the third and subsequent treatment cycles.
15 . The method of claim 14 wherein the dosing regimen comprises administering (S,S)-(HO)2DEHSPM daily for 5 consecutive days at a free base equivalent dose of about 0.27 mg/kg/day during the first week of each of the first two treatment cycles, followed by administering (S,S)-(HO)2DEHSPM at a free base equivalent dose of about 0.21 mg/kg/day to about 0.34 mg/kg/day on days 1, 8 and 15 of the third and subsequent treatment cycles.
16 . (canceled)
17 . The method of claim 15 , wherein treatment is continued until the total cumulative free base equivalent dose is about 8.2 mg/kg or less.
18 . The method of claim 17 , wherein treatment is continued until the total cumulative free base equivalent dose is about 3.4 mg/kg to about 6.9 mg/kg.
19 . The method of claim 17 , wherein treatment is continued until the total cumulative free base equivalent dose is about 5.8 mg/kg to about 6.5 mg/kg.
20 . (canceled)
21 . The method of claim 14 , further comprising co-administering GEM/NAB during each of the treatment cycles.
22 . The method of claim 21 , wherein GEM/NAB is administered on days 1, 8 and 15 of each treatment cycle.
23 . (canceled)
24 . The method of claim 14 , wherein the free base equivalent dose of (S,S)-(HO)2DEHSPM is selected from 0.14 mg/kg/day, 0.27 mg/kg/day, and 0.41 mg/kg/day.
25 - 30 . (canceled)
31 . A method of treating cancer in a patient comprising administering to a patient in need thereof no more than 14 doses of (S,S)-(HO)2DEHSPM per each treatment cycle wherein dosing occurs on non-consecutive days and wherein each treatment cycle is 28 days.
32 . The method of claim 31 , wherein the patient is administered no more than 10 doses per treatment cycle.
33 . (canceled)
34 . The method of claim 31 , wherein the patient is administered (S,S)-(HO)2DEHSPM on days 1, 8 and 15 of each treatment cycle.
35 . (canceled)
36 . The method of claim 1 , wherein the (S,S)-(HO)2DEHSPM is administered as a subcutaneous injection.
37 . The method of claim 1 , wherein the (S,S)-(HO)2DEHSPM is administered as (S,S)-(HO)2DEHSPM.4HCl.
38 . (canceled)